Company news
Lantheus Holdings, Inc. news in 2020
Lantheus Holdings, Inc.'s news releases, calls and decks from 2020, newest first.
PyL™ (18F-DCFPyL), Lantheus’ PSMA-Targeted Prostate Cancer Imaging Agent, to be Used in POINT Biopharma’s PSMA-Targeted Radioligand Therapeutic Phase 3 Trial in Patients with Metastatic Castration Resistant Prostate Cancer
December 8, 2020
Lantheus Holdings Announces Acceptance and Priority Review of New Drug Application for PyLTM (18F-DCFPyL), a PSMA-Targeted Prostate Cancer PET Imaging Agent
December 8, 2020
Lantheus Holdings, Inc. Announces Agreement to Sell Its Puerto Rico Radiopharmacy and PET Manufacturing Facility and Enter into Long-Term Supply Agreement
December 2, 2020
Lantheus Holdings to Present at the 2020 Evercore ISI HealthCONx Conference
November 23, 2020
Lantheus Holdings, Inc. Announces FDA Approval of DEFINITY® Room Temperature
November 17, 2020
Lantheus Holdings Announces FDA Clearance for AI-Enabled Automated Bone Scan Index (aBSI) in Prostate Cancer on GE Healthcare’s Xeleris Platform
November 12, 2020
CORRECTION: TIME CHANGE - Lantheus Holdings to Present at November 2020 Investor Conferences
November 8, 2020
Lantheus Holdings, Inc. Reports Third Quarter 2020 Financial Results
November 4, 2020
Lantheus Holdings to Present at November 2020 Investor Conferences
November 3, 2020
Lantheus Enters into Strategic Collaboration with Insightec for Use of Microbubbles in Combination with MR-Guided Focused Ultrasound for Treatment of Glioblastoma and Neurodegenerative Conditions
October 28, 2020
Lantheus Holdings to Host Third Quarter 2020 Earnings Conference Call and Webcast on November 5, 2020 at 8: 00 a.m. Eastern Time
October 21, 2020
Lantheus Holdings Announces Presentations at the 33rd Annual European Association of Nuclear Medicine (EANM) Virtual Congress
October 7, 2020
Lantheus Holdings Submits New Drug Application to the U.S. FDA for PyL™ (18F-DCFPyL), a PSMA-Targeted Prostate Cancer Imaging Agent
September 29, 2020
Lantheus Holdings to Present at the Wells Fargo 2020 Virtual Healthcare Conference
September 2, 2020
Lantheus Holdings, Inc. Announces FDA Approval of VIALMIX® RFID Device for DEFINITY®
August 11, 2020
Lantheus Holdings, Inc. Reports Second Quarter 2020 Financial Results
July 29, 2020
Lantheus Holdings to Host Second Quarter 2020 Earnings Conference Call on July 30, 2020 at 8: 00 a.m. Eastern Time
July 22, 2020
Lantheus Holdings to Showcase the Potential of PyL™ Imaging Agent at the Virtual Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2020 Annual Meeting
June 30, 2020
Lantheus Completes Merger with Progenics
June 21, 2020
Lantheus Stockholders Approve Share Issuance For Merger with Progenics
June 15, 2020
Lantheus Holdings, Inc. Reports First Quarter 2020 Financial Results
April 29, 2020
Lantheus Holdings, Inc. Reports Preliminary Q1 Revenue Near Top End of Previously Disclosed Guidance Range; Withdraws 2020 Financial Guidance
April 8, 2020
Lantheus Holdings, Inc. to Hold 2020 Annual Meeting of Stockholders Virtually
April 5, 2020
Lantheus and Progenics Reschedule Their Respective Special Meetings of Stockholders for Proposed Merger
April 1, 2020
Lantheus Holdings, Inc. Reports Fourth Quarter and Full Year 2019 Financial Results
February 24, 2020
Lantheus and Progenics Agree to Amended Transaction Terms
February 19, 2020
Lantheus Holdings to Host Fourth Quarter and Full Year 2019 Earnings Conference Call on February 25, 2020 at 8: 00 a.m. Eastern Time
February 17, 2020
Lantheus Announces Topline Results for BENEFIT 1 LVEF Clinical Trial
February 2, 2020
Lantheus Holdings Announces Senior Leadership Appointment
January 26, 2020